Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Artemis Therapeutics, Inc. (ATMS : OTC)
 
 • Company Description   
Artemis Therapeutics Inc. provides healthcare services. The company offers The Artemis Allergy Treatment Program for people suffering from seasonal, environmental or pet allergies. Artemis Therapeutics Inc., formerly known as New York Global Innovations Inc., is based in United States of America.

Number of Employees: 1

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.20 Daily Weekly Monthly
20 Day Moving Average: 5,582 shares
Shares Outstanding: 5.15 (millions)
Market Capitalization: $16.49 (millions)
Beta: -0.96
52 Week High: $7.02
52 Week Low: $0.55
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 180.70% 195.18%
12 Week 216.83% 249.31%
Year To Date 236.84% 303.51%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
18 EAST 16TH STREET SUITE 307
-
NEW YORK,NY 10003
USA
ph: 646-233-1454
fax: 800-253-5177
ir@artemis-therapeutics.com http://www.artemis-therapeutics.com
 
 • General Corporate Information   
Officers
Chanan Morris - Chief Financial Officer
Israel Alfassi - Director
Dana Wolf - Chief Scientific Officer
Israel Alfassi - Director
Gadi Peleg - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Medical Services
Sector: Medical
CUSIP: 04302Q109
SIC: 2890
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/22/22
Share - Related Items
Shares Outstanding: 5.15
Most Recent Split Date: 12.00 (0.02:1)
Beta: -0.96
Market Capitalization: $16.49 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/22/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -1,150.00
12/31/21 - -1,237.04
09/30/21 - -1,482.76
Current Ratio
03/31/22 - 0.01
12/31/21 - 0.01
09/30/21 - 0.08
Quick Ratio
03/31/22 - -
12/31/21 - 0.01
09/30/21 - 0.08
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -487.88
12/31/21 - -
09/30/21 - -557.58
Book Value
03/31/22 - -0.10
12/31/21 - -0.10
09/30/21 - -0.09
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©